FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014512620> ?p ?o ?g. }

• W3014512620 endingPage "2079" @default.
• W3014512620 startingPage "2070" @default.
• W3014512620 abstract "Aims To investigate the effects of the strong cytochrome P450 (CYP) 3A inhibitor itraconazole and the strong CYP3A inducer rifampicin on the pharmacokinetics of single‐dose esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, in healthy Japanese subjects. Methods Two open‐label, single‐sequence, crossover studies were conducted in healthy Japanese males aged 20–45 years. In Study 1 ( n = 20), subjects received a single oral 2.5 mg dose of esaxerenone (Days 1, 13), with itraconazole 200 mg twice daily (Day 8) and once daily (Days 9–16). In Study 2 ( n = 12), subjects received a single oral 5 mg dose of esaxerenone (Days 1, 13), with rifampicin 600 mg once daily (Days 8–16). The plasma concentration of esaxerenone and esaxerenone metabolites were measured using liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were calculated using noncompartmental analysis, and safety was assessed. Results Esaxerenone exposure increased when coadministered with itraconazole. Geometric least‐square mean ratios (90% confidence interval) of peak plasma esaxerenone concentration (C max ), area under the plasma concentration–time curve (AUC) from zero until the last measurable concentration (AUC last ) and AUC from zero until infinity (AUC inf ) were 1.13 (1.05, 1.20) ng mL −1 , 1.47 (1.40, 1.54) ng h mL −1 and 1.53 (1.45, 1.62) ng h mL −1 , respectively. Esaxerenone exposure decreased when coadministered with rifampicin. Geometric least‐squares mean ratios (90% confidence interval) of esaxerenone C max , AUC last and AUC inf were 0.659 (0.599, 0.724), 0.315 (0.300, 0.332) and 0.312 (0.297, 0.328), respectively. Conclusion Itraconazole increased esaxerenone AUC inf by 53.1%, and rifampicin decreased esaxerenone AUC inf by 68.8%. These results suggest that caution is recommended when coadministering esaxerenone with strong inhibitors and inducers of CYP3A." @default.
• W3014512620 created "2020-04-10" @default.
• W3014512620 creator A5005942636 @default.
• W3014512620 creator A5014345949 @default.
• W3014512620 creator A5037571680 @default.
• W3014512620 creator A5048577166 @default.
• W3014512620 creator A5056046661 @default.
• W3014512620 creator A5068428660 @default.
• W3014512620 creator A5070125013 @default.
• W3014512620 creator A5075110572 @default.
• W3014512620 creator A5076674260 @default.
• W3014512620 creator A5078268139 @default.
• W3014512620 date "2020-05-13" @default.
• W3014512620 modified "2023-10-16" @default.
• W3014512620 title "Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects" @default.
• W3014512620 cites W2021075228 @default.
• W3014512620 cites W2055553642 @default.
• W3014512620 cites W2106737419 @default.
• W3014512620 cites W2802617131 @default.
• W3014512620 cites W2904068253 @default.
• W3014512620 cites W2946375721 @default.
• W3014512620 cites W2991065707 @default.
• W3014512620 cites W50446327 @default.
• W3014512620 cites W642118772 @default.
• W3014512620 doi "https://doi.org/10.1111/bcp.14302" @default.
• W3014512620 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7495282" @default.
• W3014512620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32250463" @default.
• W3014512620 hasPublicationYear "2020" @default.
• W3014512620 type Work @default.
• W3014512620 sameAs 3014512620 @default.
• W3014512620 citedByCount "12" @default.
• W3014512620 countsByYear W30145126202020 @default.
• W3014512620 countsByYear W30145126202021 @default.
• W3014512620 countsByYear W30145126202022 @default.
• W3014512620 countsByYear W30145126202023 @default.
• W3014512620 crossrefType "journal-article" @default.
• W3014512620 hasAuthorship W3014512620A5005942636 @default.
• W3014512620 hasAuthorship W3014512620A5014345949 @default.
• W3014512620 hasAuthorship W3014512620A5037571680 @default.
• W3014512620 hasAuthorship W3014512620A5048577166 @default.
• W3014512620 hasAuthorship W3014512620A5056046661 @default.
• W3014512620 hasAuthorship W3014512620A5068428660 @default.
• W3014512620 hasAuthorship W3014512620A5070125013 @default.
• W3014512620 hasAuthorship W3014512620A5075110572 @default.
• W3014512620 hasAuthorship W3014512620A5076674260 @default.
• W3014512620 hasAuthorship W3014512620A5078268139 @default.
• W3014512620 hasBestOaLocation W30145126201 @default.
• W3014512620 hasConcept C105795698 @default.
• W3014512620 hasConcept C112705442 @default.
• W3014512620 hasConcept C11824378 @default.
• W3014512620 hasConcept C126322002 @default.
• W3014512620 hasConcept C134018914 @default.
• W3014512620 hasConcept C142724271 @default.
• W3014512620 hasConcept C16005928 @default.
• W3014512620 hasConcept C185592680 @default.
• W3014512620 hasConcept C204787440 @default.
• W3014512620 hasConcept C27081682 @default.
• W3014512620 hasConcept C2777071850 @default.
• W3014512620 hasConcept C2778607973 @default.
• W3014512620 hasConcept C2779548794 @default.
• W3014512620 hasConcept C2781069245 @default.
• W3014512620 hasConcept C33923547 @default.
• W3014512620 hasConcept C40222840 @default.
• W3014512620 hasConcept C44249647 @default.
• W3014512620 hasConcept C526171541 @default.
• W3014512620 hasConcept C62231903 @default.
• W3014512620 hasConcept C71924100 @default.
• W3014512620 hasConcept C76318530 @default.
• W3014512620 hasConcept C87813604 @default.
• W3014512620 hasConcept C98274493 @default.
• W3014512620 hasConceptScore W3014512620C105795698 @default.
• W3014512620 hasConceptScore W3014512620C112705442 @default.
• W3014512620 hasConceptScore W3014512620C11824378 @default.
• W3014512620 hasConceptScore W3014512620C126322002 @default.
• W3014512620 hasConceptScore W3014512620C134018914 @default.
• W3014512620 hasConceptScore W3014512620C142724271 @default.
• W3014512620 hasConceptScore W3014512620C16005928 @default.
• W3014512620 hasConceptScore W3014512620C185592680 @default.
• W3014512620 hasConceptScore W3014512620C204787440 @default.
• W3014512620 hasConceptScore W3014512620C27081682 @default.
• W3014512620 hasConceptScore W3014512620C2777071850 @default.
• W3014512620 hasConceptScore W3014512620C2778607973 @default.
• W3014512620 hasConceptScore W3014512620C2779548794 @default.
• W3014512620 hasConceptScore W3014512620C2781069245 @default.
• W3014512620 hasConceptScore W3014512620C33923547 @default.
• W3014512620 hasConceptScore W3014512620C40222840 @default.
• W3014512620 hasConceptScore W3014512620C44249647 @default.
• W3014512620 hasConceptScore W3014512620C526171541 @default.
• W3014512620 hasConceptScore W3014512620C62231903 @default.
• W3014512620 hasConceptScore W3014512620C71924100 @default.
• W3014512620 hasConceptScore W3014512620C76318530 @default.
• W3014512620 hasConceptScore W3014512620C87813604 @default.
• W3014512620 hasConceptScore W3014512620C98274493 @default.
• W3014512620 hasIssue "10" @default.
• W3014512620 hasLocation W30145126201 @default.
• W3014512620 hasLocation W30145126202 @default.
• W3014512620 hasOpenAccess W3014512620 @default.
• W3014512620 hasPrimaryLocation W30145126201 @default.

• next